Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, Market Pricing Reflects Growth Expectations
· gurufocus.com
On September 06, 2026, Vaxcyte Inc (NASDAQ: PCVX) announced it will release topline results from its pivotal Phase 3 trial of the pneumococcal vaccine candidate
On September 06, 2026, Vaxcyte Inc (NASDAQ: PCVX) announced it will release topline results from its pivotal Phase 3 trial of the pneumococcal vaccine candidate...